A STUDY OF MOXONIDINE’S METABOLIC EFFECTS IN PATIENTS WITH ARTERIAL HYPERTENSION AND NIDDM

Metabolic effects of moxsonidine (cynt) were examined in 15 patients with mild and moderate arterial hypertension (blood-pressure within 140-179/90-109 mm Hg, according to recommendations of WHO and WOH ,1999) combining with compensated diabetes of type II. After 3 month of treatment with the drug (titration of dosage from 0,2 mg to 0,6 mg) significant lowering of insuline and glucose levels in blood happened; level tests were performed two hours after standard breakfast (an equivalent of the tolerance test to glucose). Average level of glucose was 9,28±0,62 mM/l before treatment and 8,44±0,51 mM/l after treatment (p<0,04). Indicated results show an improvement of tissue sensitivity to insuline as there is need in less insuline in need after treatment with cynt for maintenance of lowered as before treatment level of glucose. Besides, growth of cholesterol content in lipoproteids of high density occured as the result of cynt treatment of patients. A conclusion about favourable metabolic effects of cint and advisability of its usage as antihypertension drug for patients with AG and diabetes of type II was drawn